Weight-loss drugs boost job prospects for unemployed women

In recent research conducted in the United States, Rebecca Diamond, a Harvard economist, explored the impact of GLP-1 weight-loss medications on unemployed women. The study revealed that women who began using these drugs experienced a significant increase in their employment rates, with a 27 percentage-point rise after 18 months compared to those who did not use the medications. This finding highlights the so-called 'obesity penalty' that heavier women face in the labor market, where they often earn less and receive fewer job callbacks than their lighter counterparts.

The research utilized data from the Understanding America Study, a nationally representative survey of U.S. adults, to compare the employment outcomes of women who initiated a GLP-1 regimen for weight loss against those who had not. The results indicated that the employment gains were primarily observed among women who were unemployed at the start of the study, rather than those returning from retirement or disability. This suggests that the visible weight loss associated with GLP-1 usage plays a crucial role in improving job prospects for these women.

Diamond's findings also revealed that the use of GLP-1 medications not only increased employment rates but also positively influenced marriage and cohabitation rates, with a 29 percentage-point rise in these social outcomes after 18 months of treatment. However, the research pointed out that the benefits of GLP-1 drugs did not extend to women who were already employed, as their career advancement opportunities, such as raises or promotions, remained unchanged. This indicates that the 'obesity penalty' is most pronounced during the initial interview process, where first impressions are formed, rather than in the workplace itself.

The study raises important questions about access to GLP-1 medications, as early adopters tend to be financially advantaged. Diamond expressed concern that unequal access to these drugs could perpetuate social and economic disparities, allowing only a select group of women to escape the penalties associated with body size. The implications of using medical treatments as a remedy for discrimination are troubling, suggesting that while GLP-1 medications may offer a solution for some, they also highlight broader issues of inequality in healthcare access and employment opportunities.